The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc. (HUMA) Shareholders

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Humacyte, Inc. regarding a class action lawsuit due to alleged misleading statements and failures to disclose critical information during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from May 10, 2024, to October 17, 2024 [3]. - Allegations include that Humacyte's facility in Durham, North Carolina did not comply with good manufacturing practices, which included issues with quality assurance and microbial testing [3]. - It is claimed that the FDA's review of Humacyte's biologics license application would be delayed while the company addressed these deficiencies, posing a substantial risk to FDA approval of their acellular tissue engineered vessel for vascular trauma [3]. - The lawsuit asserts that the defendants made materially misleading statements about the company's business, operations, and prospects, lacking a reasonable basis [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by January 17, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [5]. - The firm seeks recovery for investors who suffered losses due to false or misleading statements that led to artificial inflation of Humacyte's stock [5].